| Filed | Form | Description | |
|---|---|---|---|
| 4/25/25 | DEFA14A | DEFA14A | → |
| 4/25/25 | DEF 14A | DEF 14A | → |
| 4/26/24 | DEFA14A | DEFA14A | → |
| 4/26/24 | DEF 14A | DEF 14A | → |
| 4/28/23 | DEFA14A | DEFA14A | → |
| 4/28/23 | DEF 14A | DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 7/28/25 | 4 | 4 | → |
| 7/28/25 | 4 | 4 | → |
| 7/28/25 | 4 | 4 | → |
| 7/28/25 | 4 | 4 | → |
| 7/28/25 | 4 | 4 | → |
| 7/28/25 | 4 | 4 | → |
| ↓ | |||
VERVE-101 and VERVE-102 are an experimental gene therapy developed by Verve Therapeutics that targets the PCSK9 gene and is intended to reduce blood cholesterol levels. It works on the same protein as the cholesterol-lowering drugs known as PCSK9 inhibitors but, unlike them, is permanent.